APA (7th ed.) Citation

DH, S., HA, M., AM, E., AS, S., SA, S., & RS, I. (2025). Liraglutide mitigates dexamethasone-induced fatty acid synthase (FASN) and the cluster of differentiation36 (CD36) expression: A potential treatment for glucocorticoid-induced non-alcoholic fatty liver disease (NAFLD). Naunyn-Schmiedeberg's archives of pharmacology, 398(7), 8567. https://doi.org/10.1007/s00210-025-03789-6

Chicago Style (17th ed.) Citation

DH, Selim, Mokhlis HA, Elsayed AM, Shatat AS, Salama SA, and Ismail RS. "Liraglutide Mitigates Dexamethasone-induced Fatty Acid Synthase (FASN) and the Cluster of Differentiation36 (CD36) Expression: A Potential Treatment for Glucocorticoid-induced Non-alcoholic Fatty Liver Disease (NAFLD)." Naunyn-Schmiedeberg's Archives of Pharmacology 398, no. 7 (2025): 8567. https://doi.org/10.1007/s00210-025-03789-6.

MLA (9th ed.) Citation

DH, Selim, et al. "Liraglutide Mitigates Dexamethasone-induced Fatty Acid Synthase (FASN) and the Cluster of Differentiation36 (CD36) Expression: A Potential Treatment for Glucocorticoid-induced Non-alcoholic Fatty Liver Disease (NAFLD)." Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 398, no. 7, 2025, p. 8567, https://doi.org/10.1007/s00210-025-03789-6.